Madrigal Pharmaceuticals (MDGL) Cash from Investing Activities Growth (3y) (2013 - 2026)
Madrigal Pharmaceuticals (MDGL) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -29.84% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.24% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -22.09% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Madrigal Pharmaceuticals | 15.79 Bn | 15.56 Bn | - | 44.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.68% |
| Dec 31, 2025 | -25.38% |
| Sep 30, 2025 | -73.00% |
| Jun 30, 2025 | 35.50% |
| Mar 31, 2025 | 43.10% |
| Dec 31, 2024 | -71.74% |
| Sep 30, 2024 | -91.73% |
| Jun 30, 2024 | -64.71% |
| Mar 31, 2024 | 70.20% |
| Dec 31, 2023 | -322.60% |
| Sep 30, 2023 | -19.08% |
| Jun 30, 2023 | -29.92% |
| Mar 31, 2023 | -78.67% |
| Dec 31, 2022 | 61.04% |
| Sep 30, 2022 | 32.08% |
| Jun 30, 2022 | -19.18% |
| Mar 31, 2022 | 162.17% |
| Dec 31, 2021 | -14.45% |
| Sep 30, 2021 | 29.68% |
| Jun 30, 2021 | 30.36% |